Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "naglazyme galsulfase is indicated for patients with mucopolysaccharidosis vi mps vi maroteaux lamy syndrome naglazyme has been shown to improve walking and stair climbing capacity naglazyme is a hydrolytic lysosomal glycosaminoglycan gag specific enzyme indicated for patients with mucopolysaccharidosis vi mps vi maroteaux lamy syndrome naglazyme has been shown to improve walking and stair climbing capacity 1" assertion.
- association label "ixinity coagulation factor ix recombinant is a human blood coagulation factor indicated in adults and children 12 years of age with hemophilia b for control and prevention of bleeding episodes perioperative management ixinity is not indicated for induction of immune tolerance in patients with hemophilia b ixinity coagulation factor ix recombinant is a human blood coagulation factor indicated in adults and children 12 years of age with hemophilia b for control and prevention of bleeding episodes perioperative management 1 ixinity is not indicated for induction of immune tolerance in patients with hemophilia b" assertion.
- association label "cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established" assertion.
- association label "cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established" assertion.
- association label "noxafil is an azole antifungal agent indicated for injection delayed release tablets and oral suspension prophylaxis of invasive aspergillus candida 1 1 oral suspension treatment of oropharyngeal candidiasis opc including opc refractory ropc to itraconazole and or fluconazole 1 2 noxafil r aspergillus candida noxafil injection is indicated in patients 18 years of age and older noxafil delayed release tablets and oral suspension are indicated in patients 13 years of age and older noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis including oropharyngeal candidiasis refractory to itraconazole and or fluconazole" assertion.
- association label "enalapril maleate is indicated for the treatment of hypertension enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive enalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology heart failure mortality trials for details and limitations of survival trials in using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warnings in considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non blacks see warnings head and neck angioedema" assertion.
- association label "ilaris is an interleukin 1b blocker indicated for the treatment of periodic fever syndromes cryopyrin associated periodi c syndromes caps familial cold autoinflammatory syndrome fcas 1 1 muckle wells syndrome mws 1 1 tumor necrosis factor receptor associated periodic syndrome traps 1 1 hyperimmunoglobulin d syndrome hids mevalonate kinase deficiency mkd 1 1 familial mediterranean fever fmf 1 1 active systemic juvenile idiopathic arthritis sjia 1 2 ilaris r cryopyrin associated periodic syndromes caps ilaris is indicated for the treatment of cryopyrin associated periodic syndromes caps in adults and children 4 years of age and older including familial cold autoinflammatory syndrome fcas muckle wells syndrome mws tumor necrosis factor receptor tnf associated periodic syndrome traps ilaris is indicated for the treatment of tumor necrosis factor tnf receptor associated periodic syndrome traps in adult and pediatric patients hyperimmunoglobulin d syndrome hids mevalonate kinase deficiency mkd ilaris is indicated for the treatment of hyperimmunoglobulin d hyper igd syndrome hids mevalonate kinase deficiency mkd in adult and pediatric patients familial mediterranean fever fmf ilaris is indicated for the treatment of familial mediterranean fever fmf in adult and pediatric patients ilaris is indicated for the treatment of active systemic juvenile idiopathic arthritis sjia in patients aged 2 years and older" assertion.
- patient_undergoing_PCI label "patient undergoing PCI" assertion.
- cost-effective_treatment label "cost-effective treatment" assertion.
- association label "this association" assertion.
- readableassertion label "describe the assertion concisely (e.g. tylenol treats pain in adults patients)" assertion.
- subject label "search for the indicated drug" assertion.
- cohortAgeLabel label "describe the life stage or age of the cohort (e.g. Adults)" assertion.
- cohortAgeMax label "describe the maximum age of the cohort (e.g. 80)" assertion.
- objectNarrower label "optionally provide a narrower concepts for the disease" assertion.
- publication label "add the URL of a publication supporting this association (doi, PubMed...)" assertion.
- associationRelation label "provide the type of drug indication" assertion.
- object label "search for the disease it treats" assertion.
- cohortAgeMin label "describe the minimum age of the cohort (e.g. 7)" assertion.
- cohort label "the study cohort" assertion.
- hasPhenotype label "provide additional phenotypes for the cohort" assertion.
- assertion label "Defining a drug indication with its context (BioLink model)" assertion.
- narrow_match label "has more specific concept" assertion.
- narrow_match label "narrow match - a list of terms from different schemas or terminology systems that have a narrower, more specific meaning. Narrower terms are typically shown as children in a hierarchy or tree." assertion.
- narrow_match label "narrow match - a list of terms from different schemas or terminology systems that have a narrower, more specific meaning. Narrower terms are typically shown as children in a hierarchy or tree." assertion.
- openbiodiv-knowledge-graph label "OpenBiodiv knowledge graph" assertion.
- semantic-triples-extracted-from-biodiversity-literature label "semantic triple extracted from biodiversity literature" assertion.
- biodiversity-data-reuse label "biodiversity data reuse" assertion.
- spi label "The OpenBiodiv knowledge graph contains semantic triples extracted from biodiversity literature" assertion.
- obesity-wih-metabolic-abnormality label "obesity with metabolic abnormality" assertion.
- obesity-wih-metabolic-abnormality label "obesity wih metabolic abnormality" assertion.
- object label "search for the disease it treats" assertion.
- readableassertion label "describe the assertion concisely (e.g. tylenol treats pain in adults patients)" assertion.
- cohortAgeMax label "describe the maximum age of the cohort (e.g. 80)" assertion.
- cohort label "the study cohort" assertion.
- subject label "search for the indicated drug" assertion.
- association label "this association" assertion.
- hasPhenotype label "provide additional phenotypes for the cohort" assertion.
- cohortAgeLabel label "describe the life stage or age of the cohort (e.g. Adults)" assertion.
- publication label "add the URL of a publication supporting this association (doi, PubMed...)" assertion.
- cohortAgeMin label "describe the minimum age of the cohort (e.g. 7)" assertion.
- associationRelation label "provide the type of drug indication" assertion.
- assertion label "Defining a drug indication with its context (BioLink model)" assertion.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.
- C4726677 label "remdesivir" provenance.